p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?

Citations Over TimeTop 10% of 2002 papers

Abstract

The p63 protein, a member of the p53 family of nuclear transcription factors, is characterized by different capabilities of transactivating reporter genes, inducing apoptosis, and functioning as dominant-negative agent. This study evaluated the prevalence and prognostic implications of p63 immunoreactivity in 221 patients with stage I non-small cell lung carcinoma (NSCLC) and in 57 patients with stage I-IV neuroendocrine tumours (NET). The results were correlated with the tumour proliferative fraction, the accumulation of p53 protein, and with patient survival. p63 immunoreactivity was seen in 109/118 squamous cell carcinomas, 15/95 adenocarcinomas, 2/2 adenosquamous carcinomas, 4/6 large cell carcinomas, 9/20 poorly differentiated NET, and 1/37 typical and atypical carcinoids (p < 0.001). Furthermore, the prevalence of p63-immunoreactive cells increased progressively from pre-neoplastic and pre-invasive lesions to invasive squamous cell carcinomas. In these latter tumours, but not in adenocarcinomas, p63 immunoreactivity correlated directly with the tumour proliferative fraction (p = 0.028), and inversely with the tumour grade (p = 0.004). No relationship was found with p53 protein immunoreactivity or the other clinico-pathological variables examined. Although p63 is likely to be involved in the development of pulmonary squamous cell carcinoma, it does not carry any prognostic implication for NSCLC patients.

Related Papers

• → Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung(2003)80 cited
• → Adenosquamous Carcinoma of the Lung: Surgical Results Compared with Squamous Cell and Adenocarcinoma(1999)36 cited
• → Prognostic significance of squamous differentiation in stage I endometrial adenocarcinoma(1987)15 cited
• → A clinicopathologic study of the resected cases of adenosquamous carcinoma of the lung.(1998)7 cited
• → Adenocarcinoma versus adenosquamous carcinoma of the cervix: A comparison of diagnostic, clinical and pathological outcomes(2010)1 cited